Dementia
A progressive syndrome of cognitive decline affecting daily life.
Dementia is a syndrome classified as a major neurocognitive disorder, most commonly linked to neurodegenerative diseases like Alzheimer's. It involves a broad decline in cognitive abilities that impairs everyday functioning, including memory, thinking, behavior, and motor control. Beyond memory loss and disrupted thought patterns, common symptoms encompass emotional difficulties, language problems, and reduced motivation. These symptoms typically progress through several stages in a continuous manner. The condition is incurable and progressive, with severity ranging from mild to major, and it exists in many subtypes. Its impact is profound, affecting not only the individual but also caregivers and social relationships. Dementia is distinct from normal age-related cognitive decline and does not involve a change in intelligence.
The most frequent form is Alzheimer's disease. Dementia can also result from brain injuries or stroke. It is described as a spectrum of disorders, with subtypes named after the underlying cause: for example, Parkinson's disease dementia, Huntington's disease dementia, vascular dementia, HIV dementia, frontotemporal dementia, dementia with Lewy bodies, and prion diseases. Subtypes may also be classified by the misfolded proteins involved, such as synucleinopathies or tauopathies. When more than one type occurs together, it is called mixed dementia.
Diagnosis typically relies on the illness history and cognitive testing, supplemented by imaging to identify the subtype and exclude other causes. Blood tests rule out reversible conditions like hypothyroidism. Fluid biomarkers in cerebrospinal fluid or blood can identify Alzheimer's, while PET scans detect amyloid beta and tau proteins, the hallmark features of that disease. Although aging is the greatest risk factor, dementia is not a normal part of aging; many people over ninety show no signs. Risk factors, diagnosis, and caregiving are influenced by cultural and socio-environmental factors, and some risks like smoking and obesity are modifiable. Dementia is the seventh leading cause of death worldwide, with millions of new cases annually, and is the leading cause of death in the UK. It is a major cause of disability in those over sixty-five. There is no known cure. Acetylcholinesterase inhibitors like donepezil may offer minor benefits in mild to moderate stages of some subtypes.
Quick Facts
- Field
- Geriatrics Neurology
- Psychiatry
- Neuropsychiatry
- Symptoms
- Decreased ability to think and remember
- problems with language
- decreased motivation
- Complications
- Include malnutrition
- dehydration
- pneumonia
- injuries from falls
- Onset
- Varies, usually gradual
- Duration
- Varies, usually long term
- Causes
- Neurodegeneration
- vascular disease
- stroke
- traumatic brain injuries
- Diagnosis
- Clinical assessment
- cognitive testing (mini–mental state examination)
- and imaging
- Differential
- Delirium
- depression
- hypothyroidism
Facts from the source article.
Lore & Background
Dementia is not a single disease but a spectrum of disorders with subtypes based on the underlying cause, such as Alzheimer's disease, vascular dementia, frontotemporal dementia, dementia with Lewy bodies, and others. The coexistence of more than one type is known as mixed dementia. Diagnosis is usually based on history of the illness and cognitive testing with imaging, which can help determine the subtype and exclude other causes. Blood tests are taken to rule out reversible causes such as hypothyroidism, and fluid biomarkers in cerebrospinal fluid or blood can identify Alzheimer's disease. PET scans can detect amyloid beta and tau proteins, the hallmark features of Alzheimer's.
Reader's Guide
In the UK it is the leading cause of death. It is one of the main causes of disabilities in those aged over 65. Although the greatest risk factor is aging, dementia is not a normal part of the aging process; many people aged 90 and above show no signs. Risk factors such as smoking and obesity are modifiable by lifestyle changes. There is no known cure, but acetylcholinesterase inhibitors like donepezil may offer minor benefit in mild to moderate stages. Cognitive behavioral therapy may help with associated depression. The condition affects not only the individual but also caregivers and social relationships, and its diagnosis and caregiving practices are influenced by cultural and socio-environmental factors.
The Spectrum of Lewy Body Disease
Lewy body dementia is not a single condition but an umbrella term encompassing two closely related and common subtypes: dementia with Lewy bodies and Parkinson's disease dementia. Both are marked by progressive changes across thinking, movement, behavior, and mood, and researchers increasingly view them as points along a shared spectrum that also includes Parkinson's disease itself. The key clinical distinction between the two dementias hinges on the timing of symptom onset—whether cognitive decline arrives before or alongside parkinsonian motor symptoms (DLB) or after Parkinson's disease is already well established (PDD). Despite this diagnostic difference, autopsy findings reveal remarkably convergent neuropathological changes in both conditions. The MeSH classification system lists Lewy body disease across multiple categories, including as a basal ganglia Parkinsonian movement disorder, a brain dementia, a neurodegenerative synucleinopathy, and a neurocognitive disorder, reflecting just how many facets of the nervous system it touches. Some experts argue the phrase 'diseases with Lewy bodies' better captures this overlap than the singular 'Lewy body disease.'
The Protein Puzzle at the Heart of the Brain
The precise cause of Lewy body dementias remains unknown, but the hallmark finding is widespread deposits of abnormal protein clumps within neurons of the affected brain. These structures—Lewy bodies, first identified in 1912 by Frederic Lewy, and the thread-like Lewy neurites—have been traced to the aggregation of misfolded alpha-synuclein, a protein normally thought to assist in neurotransmitter release and vesicle turnover. Whether these misfolded proteins are actually responsible for the neurodegenerative damage, or merely a byproduct of it, has not been definitively resolved; no conclusive causal link between Lewy bodies and neuronal death has been established. The deposits affect both the central nervous system and the autonomic nervous system, which helps explain the broad range of symptoms seen in patients. In DLB, Lewy bodies cluster primarily in cortical regions, while in PDD they concentrate in the subcortical basal ganglia. A shared genetic architecture predisposes individuals to various disease phenotypes across Parkinson's disease and the Lewy body dementias, suggesting a common biological underpinning even where the outward symptoms diverge significantly.
The Diagnostic Challenge
Because the neuropathological features of DLB and PDD are highly variable and overlap substantially, the two conditions cannot be reliably distinguished by pathology alone. The primary clinical differentiator is the sequence in which symptoms emerge: if cognitive impairment begins before or simultaneously with parkinsonian motor signs, the diagnosis leans toward DLB; if Parkinson's disease is already well established and dementia arrives later, the label becomes PDD. This timing-based distinction, while practical, does not fully capture the biological continuum the two conditions represent. As of 2014, Lewy body dementias were more frequently misdiagnosed than any other common dementia, a problem compounded by the fact that most individuals with DLB had never heard of the condition before their diagnosis. General public awareness lags far behind that of Alzheimer's and Parkinson's, even though LBD ranks as the second most common dementia. This knowledge gap carries serious health consequences, particularly because people with LBD exhibit severe sensitivity to antipsychotic medications that are commonly prescribed to manage behavioral symptoms, potentially causing dangerous adverse reactions.
Living with the Diagnosis: Advocacy and Human Stories
Between five and twenty-five percent of all diagnosed dementias in older adults are attributable to one of the Lewy body dementias, affecting approximately 1.3 million people in the United States and 140,000 in the UK as of 2014. The condition typically emerges after age fifty, with men slightly more likely to receive a diagnosis than women. Following a diagnosis, average life expectancy ranges from five to eight years, a sobering reality for families navigating the journey. Organizations such as the Lewy Body Dementia Association and the UK Lewy Body Society work to close the awareness gap, reduce costly healthcare utilization, and ease the stress on caregivers. Similar advocacy groups operate in Argentina, Australia, and Japan. The human toll was starkly illustrated by the death of actor Robin Williams in August 2014; his widow revealed that an autopsy revealed diffuse Lewy body disease, a finding that underscored how the vocabulary surrounding Lewy pathology can itself cause confusion. For families, the combination of misdiagnosis, limited public knowledge, and the severity of the condition makes advocacy and community support not just helpful but essential.
More in Common Diseases & Disorders
Spotted an error? Know more?
Reader corrections go straight into our review queue. Suggest an edit · How this site is sourced